Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
UCB makes and sells medicines for brain and immune system diseases.
UCB is a biopharmaceutical company that discovers, develops, and sells drugs for two big areas of medicine: the brain and the immune system. Its medicines treat conditions like epilepsy, severe allergies, and autoimmune diseases, and they are sold around the world to patients and the doctors who prescribe them.
The company's biggest business today is immunology, where its star drug is bimekizumab (branded Bimzelx), which treats conditions such as plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. In neurology, UCB sells medicines for epilepsy, including brivaracetam (Briviact), and for rare forms of epilepsy. It also sells treatments for severe allergic conditions like chronic hives and food allergies. The pattern is consistent: UCB focuses on long-term, chronic diseases where patients keep taking medicine for years, which makes for steady revenue. UCB earns money by selling these drugs to hospitals, clinics, and pharmacies, mostly in the US and Europe. It competes with much larger drugmakers such as Novartis and Pfizer, and the field is crowded, so it tries to stand out by making clearly better medicines rather than "me-too" copies. New blockbuster drugs don't come cheap鈥擴CB spends heavily on research and on clinical trials, and many experiments fail. But when a drug works, patents give it years of protected sales, and that's where the money comes from. Its newer drugs, especially Bimzelx, have been growing fast, and the company is working to widen their use for more conditions.
Like all drugmakers, UCB faces a constant threat: when a patent on an old drug expires, cheap copies flood the market and revenue from that drug shrinks. UCB is managing this by shifting from older medicines to newer ones. Its challenge is to keep the pipeline full鈥攆inding the next big drug before today's blockbusters lose their protection.
Saved answer 路 last researched 15 Nov 2026